Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tiotropium + olodaterol
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**Tiotropium + olodaterol** is a once-daily inhaled fixed-dose dual bronchodilator for maintenance treatment of chronic obstructive pulmonary disease. It combines tiotropium, a long-acting muscarinic antagonist that reduces cholinergic bronchoconstriction, with olodaterol, a long-acting beta2-adrenergic agonist that relaxes airway smooth muscle. The combination is delivered as a soft-mist inhalation solution through the Respimat inhaler and is marketed by Boehringer Ingelheim under brands including Stiolto Respimat and Spiolto Respimat. It is intended for long-term maintenance therapy rather than rescue treatment of acute bronchospasm and is not indicated for asthma. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e15aee-40e0-23f3-537f-c96dd63e2cb1))
- Brand names
- Inspiolto RespimatSpiolto RespimatStiolto RespimatVahelva RespimatYanimo Respimat
- Other names
- olodaterol + tiotropiumolodaterol/tiotropiumTio/Olotiotropium + olodaterol fixed-dose combinationtiotropium bromide + olodaterol hydrochloridetiotropium/olodaterol
02
Targets
CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on tiotropium + olodaterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tiotropium + olodaterol.